Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease

Physician
Bjørn Stæhr Madsen
Department of Medical Gastroenterology, Odense University Hospital

Projekt styring

Projekt status	Active



Data indsamlingsdatoer
Start	01.01.2015
Slut	31.12.2017

Projektet i tal

OPEN undersøgelse/kliniske data
Forventet # af deltagere	136
Inkluderet antal deltagere	135



OPEN Biobank
Forventede deltagere med prøver	136
Inkluderede deltagere med prøver	137
Prøver	17.952

Anti-fibrotic and molecular aspects of rifaximin in alcoholic liver disease

Short summary

This project is part of the GALAXY consortium (Gut-and-liver-axis in alcoholic liver fibrosis), which is exploring the role of the gut microbiome in alcoholic liver fibrosis to improve understanding, diagnosis, prevention and treatment of chronic liver disease. Additionally, the following projects are also a part of the GALAXY consortium: OP_40 and OP_239.